Kisspeptin Canada: What Has Actually Been Tested in People?

People searching kisspeptin canada are often trying to answer several different questions at once: what kisspeptin is, whether it has been tested in people, and whether it is an authorized Canadian medicine. Those answers are not interchangeable. Kisspeptin is a signalling peptide involved in the brain-to-ovary and brain-to-testis communication that governs reproductive hormones.

The human evidence is real, but tightly bounded. Small controlled studies have measured short-term hormone changes, brain-imaging responses, and one IVF outcome in carefully selected participants. They do not establish benefits for general hormone health, perimenopause, menopause, or long-term sexual wellbeing. Health Canada database searches verified October 7, 2026, found no authorized kisspeptin drug.

Research Confidence

★★★★☆

Several controlled human studies show that kisspeptin-54 can rapidly change reproductive-hormone signalling. The strongest applied outcome comes from a 62-person phase 2 IVF trial, but the studies are short, small, and focused on different questions. There are no menopause-specific or long-term outcome trials.

Study Snapshot

• Study type: phase 2, randomized, blinded, placebo-controlled IVF trial
• Participants: 62 women aged 18-34 years at high risk of ovarian hyperstimulation syndrome
• Duration: one IVF cycle through retrieval, transfer where applicable, and early follow-up
• Measured: proportion reaching at least 60% mature-oocyte yield
• Found: 21 of 31 women given a second kisspeptin-54 injection met the threshold, versus 14 of 31 given saline
• Funding: Medical Research Council, Wellcome Trust, and NIHR

Why This Matters: Kisspeptin Canada Searches Often Blur Research and Authorization

Reproductive hormone changes can feel deeply personal: an IVF cycle with a narrow window, irregular ovulation, or sexual desire that has changed without an obvious explanation. That makes a peptide associated with reproductive signalling understandably interesting.

But a change in luteinizing hormone, often shortened to LH, is not the same thing as a durable health outcome. LH is one message in the hormonal relay between the brain and reproductive organs. Think of it as a signal sent down a telephone line, rather than proof that every part of the system has reached its intended destination.

That distinction matters especially when reading about kisspeptin canada. The available studies used clinical-grade kisspeptin-54 in monitored research settings. They did not test broad self-directed use, and they did not establish a Canadian drug indication.

The Human Signal: Short-Term Hormone Release Is the Clearest Finding

Kisspeptin sits high in the reproductive signalling chain. Researchers study it because it can stimulate release of gonadotropins, including LH and follicle-stimulating hormone, or FSH. Those hormones help coordinate ovarian and testicular function.

In a 2025 randomized, double-blind, placebo-controlled crossover study, 34 adults attended brief research visits in which each participant could be compared with themselves under kisspeptin-54 and saline conditions. The group included 12 healthy men, 12 healthy women, and 10 women with hypothalamic amenorrhea, a condition involving absent menstrual periods linked to reduced brain signalling.

Healthy women received intranasal kisspeptin-54 at 12.8 nmol/kg during two four-hour visits. Their LH response was larger than with saline placebo, while estradiol and progesterone did not significantly change during that observation window. No adverse events were reported. This was an acute physiology study, not a test of fertility, menstrual recovery, or menopause symptoms.

The Applied Endpoint: An IVF Trial Measured Oocyte Maturation

The most clinically concrete result comes from a 2017 phase 2 randomized, blinded, placebo-controlled IVF trial. All 62 participants received subcutaneous kisspeptin-54 before egg retrieval; 31 were randomly assigned a second 9.6 nmol/kg dose 10 hours later and 31 received a saline injection instead.

The primary endpoint was not pregnancy or live birth. It was whether at least 60% of eggs from sufficiently large follicles were mature—a laboratory milestone that matters in IVF, but is still one step along a longer process. Twenty-one participants in the second-dose group reached that threshold, compared with 14 in the saline group: a 26-percentage-point absolute difference.

That is a meaningful result for the specific setting studied: women aged 18 to 34 at high risk of ovarian hyperstimulation syndrome during a managed IVF cycle. The investigators themselves said direct comparison with established egg-maturation triggers was still needed. It should not be stretched into a claim about fertility outside IVF.

Other Questions: Brain Imaging and PCOS Remain Preliminary

Sexual desire research has produced an intriguing but limited signal. In a 2022 randomized, double-masked, placebo-controlled crossover trial, 40 premenopausal women with hypoactive sexual desire disorder were randomized and 32 completed both visits. Each visit involved a 75-minute intravenous kisspeptin-54 or placebo infusion, separated by at least one month.

Its primary endpoint was functional MRI, which tracks changes in blood oxygenation associated with brain activity while participants viewed erotic and facial-attraction stimuli. The completed sample had changes in prespecified brain-response measures during kisspeptin exposure, and no adverse effects were reported. The trial did not test whether sexual desire improved and stayed improved in everyday life.

A 2019 exploratory human cohort studied 12 women with anovulatory polycystic ovary syndrome, or PCOS. It had no placebo group. Participants received subcutaneous kisspeptin-54 twice daily for 21 days, with ultrasound and hormone monitoring. Two women ovulated, one showed follicle growth without ovulation, one showed diminishing response, and the others had no follicular response. That variation is precisely why an uncontrolled 12-person cohort cannot answer whether kisspeptin improves PCOS outcomes.

For context on how laboratory peptides differ from medicines evaluated in clinical trials, see understanding research peptides.

What This Means For You: Separate a Hormone Signal From a Proven Outcome

If your question is whether kisspeptin changes reproductive hormone signalling in people, the answer is yes: controlled studies have observed short-term effects on LH and related measures. If your question is whether it improves fertility, sexual desire, PCOS, or midlife symptoms in a durable way, the evidence is much less complete.

A useful conversation with a fertility or reproductive-health clinician starts with the actual problem being evaluated: ovulation, IVF planning, menstrual changes, libido, medication effects, or symptoms that overlap with perimenopause. The existing kisspeptin literature does not replace that assessment, and it does not license expectations based on a four-hour hormone study or an imaging experiment.

What This Tells Us About Women Specifically: The Data Are Young and Premenopausal

Women feature prominently in this literature, but not in the way a midlife reader may hope. The IVF trial included only women aged 18 to 34. The sexual-desire trial enrolled premenopausal women, with a mean age of 29.2 years. The 2025 hormone study included healthy women and women with hypothalamic amenorrhea, and reported results separately by sex.

None of the reviewed studies recorded or analysed perimenopausal status, postmenopausal status, or hormone therapy use. No usable evidence here addresses hot flashes, cycle changes in midlife, menopause-related sexual concerns, pregnancy safety, breastfeeding, or long-term outcomes. Male data cannot fill those gaps, because reproductive hormone signalling differs by sex and life stage.

Questions This Study Couldn't Answer: Long-Term Outcomes and Canadian Drug Status

The evidence leaves several important questions open:

• The IVF trial did not compare kisspeptin-54 directly with established maturation triggers on live birth or longer-term safety.
• The sexual-desire study measured immediate brain and questionnaire responses, not sustained clinical improvement.
• The PCOS cohort had only 12 participants, no placebo comparator, and variable responses; it also involved Ferring Research Institute support and author relationships with the company.
• No reviewed study tested perimenopausal or postmenopausal participants, or followed people long enough to assess durable outcomes.
• Health Canada database searches found no kisspeptin drug authorization. Research findings do not change that regulatory status.

Future Research: The Outcomes That Would Clarify Kisspeptin Canada Questions

Confidence would rise with larger, independently replicated randomized trials that measure outcomes people can feel and use: live birth, sustained symptom change, and carefully reported adverse events. Direct IVF comparisons with established approaches are also needed. Dedicated studies in clearly described midlife populations would be necessary before drawing conclusions about perimenopause or menopause.

Research Use And Availability

Nuforme supplies Kisspeptin for laboratory research in Canada. This research-use designation does not mean the material is a Health Canada-authorized drug, and it should not be confused with the clinical-grade kisspeptin-54 formulations studied in published trials. The human evidence described above remains indication-specific and does not establish general use.

Final Thoughts: A Real Research Signal, Not a General Hormone Answer

Kisspeptin has moved beyond theory: human trials show that kisspeptin-54 can alter reproductive hormone signalling, and one small IVF trial reported a specific maturation outcome. But for a broad kisspeptin canada search, the honest answer is narrower than the interest around it. There is no authorized Canadian kisspeptin drug, and no evidence here that answers the much bigger questions of menopause, long-term sexual wellbeing, or general hormone health.